Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP 690,550 in Patients With Active Rheumatoid Arthritis on Background Methotrexate

Trial Profile

Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP 690,550 in Patients With Active Rheumatoid Arthritis on Background Methotrexate

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL-Standard
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Jun 2018 Results of pooled data from 4 Phase 2 trials (NCT00413660; NCT00550446; NCT00603512; NCT00687193) and 5 Phase 3 randomised, double-blind, placebo-controlled trials (ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]; ORAL Step [NCT00960440]), were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of a pooled analysis of three studies (ORAL-Standard, ORAL-Sync, ORAL-Scan) assessing distinct disease activity trajectories in RA patients, presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Pooled analysis results from this, ORAL Scan, ORAL Sync, ORAL step, OPAL broaden and OPAL beyond were presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top